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1. Introduction 
Focal segmental glomerulosclerosis (FSGS) as the name implies is a histopathological 
pattern of lesions, where the “focal” refers to, involving minority of glomeruli and the 
“segmental” refers to, involving a portion of the glomerular capillary tuft caused by injury 
to podocytes (Fig 1A). Clinically it manifests proteinuria which can progress to nephrotic 
syndrome and eventually to end stage renal failure. 
1.1 Historical aspects 
Karl T. Fahr, a German pathologist, described “Progressive lipoid nephrosis” in 1925 which 
is currently recognized as FSGS. Arnold Rich (1957) was the first to report segmental 
sclerosis in juxtamedullary glomeruli in autopsy cases of children with nephrosis and 
uremia. In this report, he hypothesized that the progression to end stage renal disease 
(ESRD) in a subset of children with idiopathic nephrotic syndrome was because of the 
development of glomerular sclerosis. Churg et al published histopathological classification 
of nephrotic syndrome in children for the International Study of Kidney Disease in Children 
(ISKDC) in 1970, and the disease entity of FSGS was emphasized as a clinicopathological 
entity separate from minimal change disease (MCD) by its marked resistance to steroids and 
progression to ESRD. Habib (1973) described clinical and histopathological features of this 
entity as a separate disease entity using the term ‘focal glomerular scleroses’. 
Brown et al (1978) reported the malignant form of FSGS, which is characterized by FSGS 
with rapid decline in renal function. Howie et al. (1984) described the glomerular tip lesion 
in FSGS, as glomeruli with segmental lesions at the outer 25% with adhesion or prominence 
of podocytes at the tubular neck. Patients with the glomerular tip lesion often develop 
nephrotic syndrome and have excellent response to steroids, favorable outcome, and their 
clinical course is similar to that of patients with MCD. Schwartz et al. (1985) reported 
another form of FSGS-related cellular lesion characterized by glomerular extracapillary 
epithelial hypercellularity and endocapillary hypercellularity with foam cells and 
infiltrating leukocytes, and this was considered to represent an early stage in the 
development of FSGS. Soon after a collapsing form of FSGS as a new clinic-pathological 
entity was described by Weiss et al. (1986), which is characterized by nephrotic syndrome 
with progressive irreversible ESRD and by glomerular collapse with epithelial 
hypercellularity. Subsequently, many cases of renal disease associated with HIV infection, 
(Rao TK et al 1984) termed as HIV-associated nephropathies, were reported with features 
similar to the collapsing form of FSGS..  
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Between 1980–2000, secondary FSGS (Rennke HG et al. 1989 & D’Agati V. 1994) was 
established as FSGS with recognized etiologic associations, including genetic mutations in 
podocyte-associated proteins, virus, drug toxicities, and structural–functional adaptations. 
Finally in 2004, the Columbia classification was proposed by D’ Agati, Fogo, Bruijn, and 
Jenette, as a working classification for FSGS as given in table 2. Lately some celebrity figures 
like Sean Elliott and Alonzo Mourning (National Basketball Association) have been 
diagnosed with FSGS which has further enhanced awareness of this disease in public. 
1.2 Epidemiology 
Focal segmental glomerulosclerosis (FSGS) currently is the leading cause of  
nephrotic syndrome in adults and children, particularly in the United States, Australia, 
Brazil, Canada, Kuwait, India and many other countries. (reference from: 
http://eng.hi138.com/?i295373_The-epidemiology-of-focal-segmental-glomerulosclerosis). 
Renal biopsy survey for idiopathic nephrotic syndrome in adults in United States between 
1995 to 1997, has revealed that FSGS is the most common cause of nephrotic syndrome, 
responsible for 35 percent of all cases and more than 50 percent of cases among black 
population, (67 percent of such cases in black adults were younger than 45 years of age). 
Idiopathic FSGS is now the most common cause of end stage renal disease (ESRD) caused by 
primary glomerular disease in the United States in both the black and white populations. 
The proportion of ESRD attributed to FSGS has increased 11-fold, from 0.2% in 1980 to 2.3% 
in 2000 (excluding patients with HIV). As per Kitiyakara C. et al (2004) the peak decade for 
FSGS ESRD incidence is 40 to 49 years among black patients as compared to, 70 to 79 years 
among white and Asian patients. Males have 1.5- to 2-fold greater risk than females. Recent 
incidence of end stage renal disease secondary to FSGS is five cases per million population 
in Caucasian US population and 30-40 cases per million population for African-American 
population (Hogg R. et al 2007).  
2. Etio-pathogenesis 
While majority of FSGS cases are still considered idiopathic, the etiologies and mechanisms 
involved in FSGS development continue to be elucidated. FSGS can be divided into primary 
or idiopathic and secondary depending upon if the etiology is unknown vs. known 
respectively. For FSGS to produce nephrotic range or non-nephrotic range proteinuria, 
alterations of normal glomerular structure and function has to occur. Normal glomerular 
function requires, that the three major components of glomerular filter, namely endothelial 
cells, podocytes, and glomerular basement membrane (GBM), be intact and are able to provide a 
permselective filtration barrier. Specialized tight junctions between podocyte foot processes 
create a slit diaphragm (SD) which is integral in preventing the loss of protein into 
Bowman’s space (Kimberly et al. 2007 & Asanma et al 2003) . Even though the clinical 
presentation of FSGS is often heterogeneous, a cardinal feature of the disease is proteinuria, 
which implies loss of this permselective barrier (Schnaper HW, 2003 & Fogo AB, 2003). 
Electron microscopic picture clearly reveals distortion of normal architecture (or effacement) 
of the foot processes of podocytes in FSGS 
(Fig 1B). 
A key factor in the pathogenesis of FSGS is damage and loss of podocytes. Asanuma K. et al. 
(2003) described that based on recent insights into the molecular pathology of podocyte 
injury, at least four major causes have been identified that lead to the uniform reaction of 
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pododcyte foot processes effacement and proteinuria: (1) interference with the slit 
diaphragm complex and its lipid rafts (2) direct interference with the actin cytoskeleton (3) 
interference with the GBM or with podocyte-GBM interaction, and (4) interference with 
negative surface charge of podocytes. Damage to podocytes triggers apoptosis and the 
detachment of podocytes from the glomerular basement membrane. The resulting reduction 
in podocyte number (podocytopenia) leaves the glomerular basement membrane to be 
exposed, (Fogo AB 2003) which leads to development of maladaptive interactions between 
the glomerular basement membrane and epithelial cells. This is followed by proliferation of 
epithelial, endothelial and mesangial cells. The combined reaction of cell proliferation and 
leakage of proteins into Bowman’s space results in deposition of the collagen. Eventually the 
capillary loop collapses and endothelial cells are lost and the affected part of the glomerular 
tuft heals by scarring causing a characteristic lesion of FSGS. Thus the lesions initially are 
limited to a few segments in the glomerulus (segmental) and in a few regions of the kidney 
(focal) but the disease ultimately progresses to involve the entire kidney leading to end 
stage renal disease (ESRD).        
The precise initial insult that leads to the above cascade of events is still unknown. A 
‘circulating permeability factor’ which leads to glomerular basement membrane injury has 
been proposed in the pathogenesis of FSGS (Shalhoub RJ, 1974). The following information 
favors the hypothesis of ‘circulating Permeability factor’ (1) frequent recurrence of 
proteinuria after renal transplant [Ingulli E. et al. 1991] (2) the efficacy of extracorporeal 
techniques such as plasmapheresis in reducing the post renal transplant proteinuria [Artero 
M. et al 1992 and 1994]. (3) the results of in vitro bioassay which detects permeability 
changes induced by FSGS serum on isolated glomeruli [Savin VJ et al in 1992 and 1996]. 
(4)Rea et al (2001) demonstrated that the main clinical feature of FSGS i.e. proteinuria, 
disappeared within one year after transplantation in two recipients of kidneys from a 
patient with FSGS. Not taking into account ethical and legal implications, good outcome of 
the FSGS allograft kidneys into non FSGS recipients is another good evidence for humoral 
genesis/circulating permeability factor, as a cause of the FSGS. (5) Kemper M. et al (2001) 
demonstrated transmission of glomerular permeability factor from the mother affected by 
FSGS to her infant during gestation. After birth, proteinuria in the child decreased and then 
disappeared, suggesting a strong correlation with some circulating factor transmitted from 
the mother to the child.  
At the molecular level, cytokines and vasoactive factors are believed to play a major role in 
the progression of FSGS. The overexpression of transforming growth factor β (TGFβ) or its 
downstream proteins, the ‘Smads’ lead to glomerulosclerosis in animal models. Activation 
of the renin-angiotensin system upregulates TGFβ, which is considered to cause further 
progression of the disease (Harris RC et al. 2006). Angiogenic factors, like platelet-derived 
growth factor (PDGF) and vascular endothelial growth factor (VEGF) seem to play a role in 
disease progression. This is based upon the rat remnant kidney model (RK model) 
experimental studies of progressive glomerulosclerosis. In this model, VEGF upregulation 
soon after the renal injury and later loss of VEGF expression correlates well with 
progression of the glomerulosclerosis (Kang DH et al. 2001). 
Mechanical stress is also believed to play a role in the progression of FSGS. (Hostetter TH. 
2003 & Kwoh C. et al 2006) The hyperfiltration due to the defects of the filtration barrier 
results in increased single nephron glomerular filtration rate (SNGFR), which results in 
hypertrophy of glomeruli. The hypertrophy exacerbates the mismatch between the 
glomerular basement membrane and the decreased numbers of podocytes, propagating the 
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injury further. Another factor in the progression of FSGS is tubulointerstitial injury. 
Clinically, tubulointerstitial injury is a predictor of the loss of renal function in FSGS 
(D’Agati VD 2003 & Rodriguez-Iturbe B et al. 2005). The nonspecific entry of proteins into 
the tubular lumen is one potential source of damage to the tubulointerstitium. Indeed, 
persistence of nephrotic-range proteinuria is a negative prognostic factor for the progression 
of FSGS to ESRD (Walls J. 2001). Cytokines (such as TGFβ), when present in the tubules, will 
recruit monocytes, macrophage, and T-cells. This stimulates other cytokines, including 
interleukin-1, tumor necrosis factor alpha, and other chemokines. This inflammatory 
infiltrate leads to mesangial matrix deposition, promoting the collapse of glomeruli. The 
cellular infiltrate and cytokines also damage tubular epithelial cells, and some tubular 
epithelial cells may undergo transformation to mesenchymal cells. These mesenchymal cells, 
as well as recruited and stimulated fibroblasts, result in collagen matrix deposition and 
tubulointerstitial fibrosis 
(Harris RC et al. 2006). 
Regardless of the cause of podocyte injury, when the podocytes start dying, leakage of 
protein across the GBM leading to proteinuria and hypoalbuminemia ensues. At this time 
cholesterol levels start rising due to increased synthesis of cholesterol by the liver and loss of 
lipid regulating proteins in the urine, the underlying mechanism of these effects is not 
completely known yet. The beneficial effects of blocking the renin-angiotensin system may 
not be limited to their antiproteinuric or antihypertensive effects. As noted earlier, 
angiotensin stimulates TGFβ, in turn contributing to fibrosis. In addition, angiotensin affects 
intracellular calcium concentrations and the podocyte cytoskeleton (Harris RC et al. 2006). 
Inhibition of angiotensin may slow progression by these local mechanisms (Korbert SM, 
2003). 
With increasing incidence of FSGS, these pathways of podocyte injury and disease 
progression provide important targets for future intervention. Trials have already been 
initiated to antagonize cytokines, such as TGFβ (as discussed later in this chapter in 
treatment section). 
Genetic mutations seen in congenital forms of nephrotic syndrome and FSGS enabled 
researchers to identify specific gene mutations involved in podocyte damage (Tryggvason 
K. et al. 2006). Mutations of the nephrin gene, a podocyte-specific transmembrane 
component of the slit diaphragm, are found in congenital Finnish-type nephrotic syndrome, 
and may lead to loss of normal caliber slit diaphragms. (Kestila M. et al. 1998, Tryggvason 
K. et al. 2006, Kwoh et al. 2006). In mouse models, mutations of nephrin-like transmembrane 
genes (NEPH-1) which also localize to the slit diaphragm result in proteinuria and early 
death. Other proteins which are part of the slit diaphragm complex include: podocin, CD2-
associated protein (CD2AP), FAT, P-cadherin,ZO-1, LAP (leucine rich repeat and PDZ 
domain) protein. (Asanuma K et al 2003, Tryggvason K. et al. 2006). Mutations in podocin (a 
transmembrane protein that interacts with nephrin, NEPH-1 and CD2AP) have been 
identified in familial FSGS. Recently, mutations in CD2AP, an immunoglobulin-like protein 
that is involved in nephrin integration with podocyte cytoskeleton, have also been linked to 
genetic forms of FSGS (Shih NY. et al. 1999, Kim JM et al 2003, Tyggvason K. et al 2006). In 
mouse models, the loss of FAT1 and FAT2 (transmembrane proteins with cadherin-like 
repeats) results in the absence of slit diaphragms, proteinuria, and early death. Alpha-
actinin-4, an important structural component of the podocyte cytoskeleton, is mutated in 
some autosomal dominant forms of FSGS (Kaplan JM et al 2000, Yao J et al. 2004). In 
addition to the abnormal structural proteins mutations, some other mutations have been 
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identified in association with FSGS like TRPC6 (Transient receptor potential cation chanel, 
subfamily C, member 6) which is a cation-selective, ion-channel protein that mediates 
calcium signals (Winn MP et al. 2005). The role of the other components of the slit 
diaphragm in the pathophysiology of FSGS is not yet clear. 
In summary, these data suggest that mutations in the cytoskeleton and membrane 
proteins specific to podocytes are responsible for most inherited forms of disease. The 
frequency of spontaneous mutations in the general population who develop nephrotic 
syndromes or FSGS still needs to be assessed as it has diagnostic, prognostic and 
therapeutic implications in case of FSGS. For example, patients who possess genetically 
defective podocytes should be unresponsive to conventional steroid treatment. Similarly, 
these patients should not have recurrent FSGS when transplanted with a structurally 
normal kidney allograft. Furthermore, family members who are potential living donors 
could be genetically screened for mutations associated with the development of kidney 
disease and excluded as candidate donors. 
3. Secondary FSGS  
Secondary FSGS can be seen in a variety of conditions such as renal agenesis, obesity, or sickle 
cell disease etc where hyperfiltration is a characteristic abnormality. Glomerulomegaly is 
common in situations with hyperfiltration. Obesity-associated FSGS needs a definitive 
diagnosis with a renal biopsy to exclude the presence of concurrent early diabetic 
nephropathy. Secondary FSGS may also result from intravenous drug abuse and reflux 
disease. It has been reported that toxins, including lithium and pamidronate, and sirolimus are 
associated with the development of FSGS lesions. Among the viral infections, HIV is the most 
common cause. Rarer viral causes of secondary FSGS include persistent parvovirus B19, 
simian virus 40, and cytomegalovirus infection. 
4. Clinical presentation 
Primary FSGS more likely presents with sudden-onset nephrotic syndrome, whereas 
secondary FSGS presents more insidiously with subnephrotic range proteinuria and renal 
insufficiency. But the secondary FSGS from pamidronate toxicity though typically 
presents with full nephrotic syndrome and acute or subacute renal failure, with collapsing 
FSGS lesions on biopsy. Physical exam reveals elevated blood pressure and edema. Urine 
may be foamy and may have hematuria. The relative frequencies of these findings at 
presentation or biopsy based diagnosis in published series (Rydell JJ et al. 1995 & Chun 
MJ et al 2004) are as follows. Primary FSGS can present with nephrotic range proteinuria 
(60 to 75%), microscopic hematuria with variable degrees of proteinuria (30 to 50% ), 
hypertension (45 to 65 %), renal insufficiency (25 to 50 %) and with overlapping of these 
presentations. Children tend to present with more proteinuria whereas hypertension is 
more common in adults. A case of FSGS should be considered idiopathic only when other 
etiologies are thoroughly excluded. Uncommonly Muehrcke’s lines (white banding on the 
nails due to hypoalbuminaemia), xanthelasma and xanthomata (cholesterol deposits in 
skin) are associated with FSGS as well. Following risk factors need to be considered when 
doing history and physical examination on such patients: male gender, black race, 
positive family history, heroin abuse, use of known causative medications, chronic viral 
infection, a solitary kidney, and obesity. 
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Primary or idiopathic FSGS: Refer to Table 2 
 
Secondary FSGS: 
1. Virus assoiated 
a. HIV associated nephropathy (HIVAN)  
b. Parvovirus B19 
c. SV40 
d. CMV 
2. Drug toxicity 
a. Pamidronate 
b. Lithium 
c. Interferon –alpha 
d. Heroin  
e. Sirolimus 
3.  Secondary FSGS mediated by adaptive structural-functional responses 
a. Reduced renal mass  
 Unilateral renal agenesis 
 Oligomeganephronia 
 Renal dysplasia 
 Reflux nephropathy 
 Sequela to cortical necrosis 
 Surgical renal ablation 
 Chronic allograft nephropathy 
 Any advanced renal disease with reduction in functioning nephrons 
b.  Initially normal renal mass 
 Obesity 
 Hypertension 
 Atheroembolic or other acute vaso-occlusive processes 
 Cyanotic congenital heart disease 
 Sickle cell anemia 
 Anabolic steroids 
4. Familial FSGS 
a. Autosomal recessive : 
 mutations in genes NPHS1 (coding for nephrin) ,NPHS2 (coding for podocin) and 
 PLCE1 (coding for PLC epsilon1) 
 LAMB2 (coding for Laminin beta 2 chain) 
b. Autosomal dominant 
 Mutations in genes ACTN1 (coding for alpha actinin4), TRPC6 (coding for TRPC6), 
 INF2 (coding for INF2) 
 WT1 (coding for WT1) 
_________________________________________________________________________________ 
 
Table 1. Etiologic Classification of Focal Segmental Glomerulosclerosis  
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Differences in clinical manifestations correlate with differences in pathologic phenotypes. 
Collapsing variant of FSGS often has more severe proteinuria and renal insufficiency but 
less hypertension than typical variant. Patients with collapsing FSGS frequently have 
extrarenal manifestations of the disease, a few weeks before the onset of the nephrosis e.g. 
episodes of upper respiratory infections, diarrhea that are usually ascribed to the viral or 
other infectious processes. However, the symptoms of fever, anorexia, aches and pains are 
present only in 20% of patients at the time of onset of nephrosis. Glomerular tip lesion 
variant (Fig 4) often presents with rapid onset of edema similar to minimal change disease. 
Glomerular tip lesion patients may develop reversible acute renal failure, at the times of 
initial presentation when the degree of proteinuria, edema, hypoalbuminemia are at their 
peak. This behaves like minimal change disease and this rarely happens in any other forms 
of FSGS. Patients with glomerular tip lesion FSGS tend to be older white males in 
comparison to younger black males predominance in collapsing variant FSGS. 
Distinguishing between primary and secondary FSGS is important, since secondary FSGS 
should not respond to immunosuppressive therapy. Instead, the inciting condition or toxin 
should be alleviated or stopped in secondary form FSGS if possible. Unfortunately, 
distinguishing between primary vs. secondary FSGS can be challenging, since focal sclerosis 
lesions may be present in a diverse assortment of glomerular, vascular, and tubular injuries, 
just as global sclerosis represents a common endpoint lesion for the end-stage renal disease. 
5. Laboratory findings 
Urine analysis may have wide range of findings starting from fatty casts to dysmorphic red 
blood cells and red blood cell casts. Proteinuria varies from less than 1 gm to 30g/day. 
Hypoproteinemia is common in patients with FSGS, with total serum protein reduced to 
varying extents. Hypoalbuminemia may drop as low as below 2 g/dL, especially in patients 
with the collapsing and glomerular tip variants of FSGS. Cholesterol levels are increased. 
Serum complement components are typically in normal range in FSGS. CD4 cell count and 
HIV test is essential in all patients with FSGS, especially those with the collapsing pattern. 
DNA/PCR for Parvo B19 and CMV test is an essential part of work up to rule out the rare 
forms of secondary FSGS. Finally renal biopsy is the final step to make the diagnosis of FSGS.  
6. Histopathology 
The diagnosis of FSGS is not an easy one to make, because the morphologic features of FSGS 
are nonspecific and can occur in a variety of other conditions or superimposed on other 
glomerular disease processes. Additionally, because the defining glomerular lesion is focal, 
it may not be adequately sampled in small needle biopsies. The diagnosis of FSGS is further 
complicated by the existence of a primary (or idiopathic) form and many secondary forms 
(Table 1). Before a diagnosis of primary FSGS can be made, secondary forms must be 
excluded. Idiopathic FSGS must be distinguished from human immunodeficiency virus 
(HIV) -associated nephropathy, heroin nephropathy and other large group of secondary 
FSGS caused by structural-functional adaptations mediated by intrarenal vasodilatation, 
and increased glomerular capillary pressures, (as listed in Table 1). The morphological types 
are not used to guide treatment but to provide useful prognostic information. Electron 
microscopy can be used to distinguish primary and secondary FSGS. In primary FSGS, foot 
process fusion is diffuse and occurs throughout the glomeruli. In secondary FSGS, foot 
process fusion is mostly limited to the sclerotic areas. 
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Five main light microscopic patterns of FSGS have been defined, as given below: 
 
 
Classified based upon the ‘Working Columbia Classification 2004’.  
Table 2. Morphological variants of FSGS 
Although appearance of the glomerular tuft differs in these forms, all share the common 
feature of podocyte alterations at the ultrastructural level. At present, it is unclear if these 
morphologic variants reflect pathogenetic differences or they are the consequence of 
different severities of podocyte injury or histopathologic evolution. Future studies are 
needed to address these questions.  
Classic Focal Segmental Glomerulosclerosis (Focal Segmental Glomerulosclerosis Not 
Otherwise Specified) : also called FSGS NOS, or typical FSGS. FSGS NOS requires exclusion of 
the other more specific subtypes described in the table 2. Light Micrscopic examination reveals 
accumulation of extracellular matrix which occlude glomerular capillaries, forming discrete 
segmental solidifications involving affected portion of the glomerular tuft. Also seen is 
plasmatic insudation of amorphous glassy material beneath the GBM, endocapillary foam 
cells, and wrinkling of the GBM. Adhesions to Bowman's capsule are common, and overlying 
visceral epithelial cells often appear swollen over the sclerosing segment. Non sclerotic 
glomerular lobules appear normal by light microscopy except for mild podocyte swelling. 
Immunofluorescence: focal and segmental granular deposition of IgM, and C3 is seen often, 
but C1 in the distribution of segmental glomerular sclerosis may also be seen. Nonsclerotic 
glomeruli may have weak mesangial staining for IgM and C3. By electron microscopic 
examination, segmental sclerotic lesions exhibit increased matrix, wrinkling and retraction 
of GBM. Accumulation of inframembranous hyaline material but no immune complex 
electron-dense deposits are seen. Overlying the segmental sclerosis, there is usually 
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effacement of foot processes (Fig 1.B)and podocyte hypertrophy. The adjacent nonsclerotic 
glomerular capillaries show only foot process effacement. 
 
   
Fig. 1. (A-left) Focal segmental distribution of glomerular lesions. The glomerulus at the top 
right of the picture is normal. The glomerulus at the bottom shows dense segmental scars 
with adhesion to Bowman's capsule. (Periodic acid methenamine silver, 20X). (B-Right) 
Patchy effacement of foot processes is present. No immune complex-type deposits are seen 
along the GBM. (Electron Microscopy).  
Perihilar Variant of Focal Segmental Glomerulosclerosis : This variant is defined as 
perihilar hyalinosis and sclerosis (Fig 2. A & B) which involves more than 50% of glomeruli 
with segmental lesions. This category requires that the cellular, tip, and collapsing variants 
be excluded. Podocyte hyperplasia is uncommon.  
 
   
Fig. 2. (A-left): Perihillar variant FSGS (B): Glomerulus with "Hyalinosis": homogeneous, 
eosinophilic material may be present at the periphery of sclerotic foci, or within the capillary 
subendothelial space (PAS, 40X). (Fig 2A-obtained from 
http://www.unckidneycenter.org/kidneyhealthlibrary/fsgs.html#causes) 
Immunofluorescence (IF) reveals segmental deposits of IgM and C3 in areas of sclerosis and 
hyalinosis.  
Electron microscopy (EM) demonstrates variable foot process effacement. The perihilar 
variant may occur in primary or secondary FSGS. It is more common in secondary forms of 
FSGS mediated by adaptive structural-functional responses, in which it is typically 
accompanied by glomerular hypertrophy. In this setting, the greater filtration pressures at 
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the proximal end of the glomerular capillary bed may favor the development of lesions at 
the vascular pole. 
Cellular Variant of Focal Segmental Glomerulosclerosis : This variant is characterized by 
focal and segmental endocapillary hypercellularity that may mimic a form of focal 
proliferative glomerulonephritis. Glomerular capillaries are segmentally occluded by 
endocapillary hypercellularity, including foam cells, infiltrating leukocytes, karyorrhectic 
debris, and hyaline. There is often hyperplasia of the visceral epithelial cells, which may 
appear swollen and crowded, sometimes forming pseudocrescents. This variant requires 
that tip lesions and collapsing lesions be excluded. 
IF shows focal and segmental glomerular positivity for IgM and C3 and EM reveals severe 
foot process effacement. 
Collapsing Variant of Focal Segmental Glomerulosclerosis: This variant is defined by at 
least one glomerulus with segmental or global collapse (Fig 3) and overlying hypertrophy 
and hyperplasia of visceral epithelial cells. There is occlusion of glomerular capillary lumina 
by implosive wrinkling and collapse of the GBMs. This lesion is more often global than 
segmental. Overlying podocytes display striking hypertrophy, hyperplasia and express 
proliferation markers. Podocytes often contain prominent intracytoplasmic protein 
resorption droplets and may fill Bowman's space, forming pseudocrescents . Although 
podocyte hyperplasia is found in both the collapsing and cellular variants of FSGS, 
collapsing glomerulopathy is distinguished by the absence of endocapillary 
hypercellularity. In collapsing FSGS, there is prominent tubulointerstitial disease, including 
tubular atrophy, interstitial fibrosis, interstitial edema, and inflammation. A distinctive 
feature is the presence of dilated tubules forming microcysts that contain loose 
proteinaceous casts. This pattern can occur both in primary FSGS and also in secondary 
FSGS due to HIV,parvovirus B12,pamidronate toxicity and interferon therapy. Endothelial 
tubuloreticular inclusions are identified in over 90% of patients with HIVinfection 
collapsing glomerulopathy and interferon therapy, whereas only in 10% cases with 
idiopathic collapsing glomerulopathy. Besides these conditions endothelial tubuloreticular 
inclusions are seen commonly in systemic lupus erythematosus nephritis.  
 
 
Fig. 3. A glomerulus displays collapsing variant of FSGS , glomerular capillaries show 
collapse with absent lumen (H&E, 40X).  
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IF microscopy of collapsing lesions often is positive for IgM and C3. EM reveals severe foot 
process effacement affecting both collapsed and noncollapsed glomeruli 
Tip Variant of Focal Segmental Glomerulosclerosis : 
This variant is defined by the presence of at least one segmental lesion involving the tip 
domain (i.e., the outer 25% of the tuft next to the origin of the proximal tubule). There is 
either adhesion (Fig 4) between the tuft and Bowman's capsule or confluence of swollen 
podocytes with parietal or tubular epithelial cells at the tubular lumen or neck. In some 
cases, the affected segment appears to herniate into the tubular lumen. The segmental 
lesions may be cellular or sclerosing type. Although initially peripherally located, these 
lesions may progress more centrally. The presence of perihilar sclerosis or collapsing 
sclerosis rules out the tip variant. 
IF microscopy reveals involved tip area positive for IgM and C3 and EM findings 
demonstrate foot process effacement. 
 
 
Fig. 4. Sclerotic glomerular segment with a small adhesion; "Glomerular tip lesion“ (Periodic 
acid methenamine silver, 40X) 
7. Treatment 
Typically the goals of treatment in FSGS include-(1) to reduce, eliminate or at least suppress 
the proteinuria and (2) to avoid or at least retard the progression to ESRD. Treatment of the 
FSGS can be arbitrarily divided into (1) Nonspecific; nutritional management (2)Non 
immunosuppressive therapy: diuretics and RAS interference. (3) Immunosuppressive 
treatment: which includes the use of steroids, steroid sparing medications like 
cyclophosphamide, cyclosporine A, tacrolimus and mycophenolic mofetil. (4)-Antifibrotic 
drugs:Pirfenidone, Rosiglitazone (FONT Phase 1 trial completed and now FONT phase II 
trial is ongoing) (5)-Monoclonal/polyclonal Antibodies: Adalimumab, Rituximab, 
Fresolmumab (6)-Plasmapheresis 
Nonspecific treatment: Nonspecific treatment goals in FSGS are like any other 
glomerulopathy associated with nephrotic syndrome, which include maintenance of 
adequate nutrition, minimization or elimination of proteinuria, and prevention of 
complications resulting from edema. The mainstay of treatment is reduction in daily salt 
intake to 2 g of sodium. A high level of protein intake may further aggravate proteinuria, 
adversely affecting renal function. Current recommendations call for an intake of 1to1.3 g of 
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high biologic value protein per kilogram of body weight and a reduction of fat intake. Lipid 
lowering is necessary to reduce cardiovascular risk and to possibly delay the progression of 
renal disease. 
7.1 Non-immunosuppressive drug treatment 
Symptomatic relief of edema helps the patient feel better. In most patients, loop diuretics are 
needed to promote diuresis. Patients with massive edema with impaired oral absorption 
may require intravenous administration of loop diuretics. In patients with refractory 
conditions, addition of other diuretics (eg, metolazone) and potassium-sparing agents (eg, 
spironolactone, triamterene) facilitates diuresis and prevents hypokalemia. Rarely, some 
patients (especially children) with intractable edema may need intravenous albumin and 
diuretics in a hospital setting to initiate diuresis. Protracted use of intravenous albumin 
should be discouraged; the regimen is expensive and ineffective, because most of the 
infused albumin is lost in the urine. Continuous IV drip of furosemide is preferred over 
large boluses of IV push to avoid side effects.  
Control of hypertension is one of the most important aspects of overall management in 
FSGS, like any other glomerular disease. Angiotensin-converting enzyme inhibitors (ACEIs) 
and angiotensin receptor blockers (ARBs) are nonspecific agents that reduce proteinuria 
because of their antihypertensive and intrarenal hemodynamic effects of reducing 
glomerular capillary pressure and resistance. ACEIs and ARBs are effective in reducing 
protein loss even in normotensive patients. These agents do have an effect in slowing down 
of the disease progression by downregulating the TGFβ by interfering with renin 
angiotensin system, regardless of any antihypertensive effects.These agents do not abolish 
proteinuria completely or reverse the primary glomerular disease process per se.  
As hypertension develops in most patients with FSGS which further causes deterioration of 
renal function, the control of blood pressure is an important part of the treatment of FSGS. 
Many patients, may require combination antihypertensive therapy to maintain blood 
pressure in the normal range. Lipid lowering therapy like statins is warranted to correct 
hyperlipidemia to reduce the risk of cardiovascular disease in this subset of patient 
population.  
7.2 Immunosuppressive treatment  
Idiopathic FSGS is a difficult disease to treat because of its highly variable clinical course. 
The specific treatment approach is still empirical, and no consensus has evolved because of a 
lack of prospective controlled trials. Current evidence is, mostly derived from retrospective 
analyses, and favors prolonged steroid therapy (6 months or longer) to induce remission in 
patients with idiopathic FSGS. 
Criteria for remission: (1) complete remission is considered when urinary protein excretion 
of less than 200-300 mg/day, and (2) partial response is considered when urinary protein 
excretion of 200-3500 mg/day, or a greater than 50% reduction in baseline proteinuria.  
Since long-term steroid therapy is not without serious toxicity, the patient counselling 
regarding the goals of the therapy, possible potential side affects and expected outcomes, is 
essential before starting such treatment. The current consensus is to initiate therapy with 
prednisone in a dose of 1 mg/kg (60-80 mg/d) for 2-6 months or longer, depending on 
patient’s response as assessed by presence or absence of edema, 24-hour urine protein 
excretions, creatinine clearance, serum creatinine, serum albumin, and lipid levels. 
Literature reveals that 30-60% of patients may undergo complete or partial remission with 
www.intechopen.com
 Focal Segmental Glomerulosclerosis 
 
37 
this treatment regimen, and relapses are frequent when steroids are discontinued. Blacks 
and patients with collapsing FSGS are generally refractory to treatment and progress to 
renal failure. In steroid responsive patients, the goal is to titrate prednisone to the lowest 
dose needed to stop proteinuria and to prevent relapses. Use of steroids on alternate days 
can also reduce toxicity. The optimal duration of treatment is uncertain; some authorities 
recommend use of steroids indefinitely. If no remission after 4 months of corticosteroid 
treatment, disease is defined as being corticosteroid-resistant (Meyrier A.,2009). 
In patients who are refractory to 2-3 months of prednisone therapy, the recommendation is 
to reduce the steroid dose and to add cyclophosphamide (2.5 mg/kg [150-200 mg/day]), 
monitor patients for bone marrow suppression, and encourage adequate fluid intake to 
prevent hemorrhagic cystitis. Prolonged use of cyclophosphamide may lead to gonadal 
toxicity; therefore, persisting with cyclophosphamide beyond 3 months in patients who do 
not respond is unwise. Cyclosporine (3.5mg/kg/day) can induce remission and preserve 
renal function, although relapse occurs in 60% of patients when cyclosporine alone is used 
(Ponticelli C. et al. 1993 & Cattran DC et al. 1999). Continuing treatment with cyclosporine 
for 1 year after remission followed by a slow tapering of the dose results in a longer 
remission (Meyrier A 1994).  Low-dose cyclosporine in combination with low-dose 
prednisone (0.15mg/kg/day) in corticosteroid-resistant patients is more effective than 
cyclosporine alone (Cattaran DC. Et al 1999 & Meyrier A 2009). Rates of complete (Niaudet 
P. 1994 & Braun N et al 2008) and partial remission achieved with cyclosporine are greater if 
low-dose prednisone is given at the same time. Continuous use of cyclosporine for >12 
months is associated with a significant increase in tubulointerstitial fibrosis. Its use should, 
therefore, be limited to patients with creatinine clearance >60 ml/min/1.73 m2 
Isolated reports have suggested that patients who are refractory to steroids and 
cyclophosphamide, treatment with other immunosuppressive agents, such as tacrolimus 
and sirolimus, may be beneficial in inducing remission. However, studies using these agents 
were uncontrolled investigations that were limited to a few patients.  
7.3 Tacrolimus 
Few studies have reported the use of tacrolimus for Idiopathic FSGS. In the largest study, 25 
patients with nephrotic syndrome due to primary FSGS and known resistance to or 
dependence on cyclosporine (cyclosporine) were given tacrolimus plus prednisolone 
(prednisone) for 6 months. Seventeen patients had a reduced proteinuria to <3 g/day, and 
12 had complete or partial remission. Thirteen patients relapsed after discontinuing 
tacrolimus; reinstitution of therapy for 1 year resulted in complete remission (5 patients) and 
partial remission (4 patients). [Segarra A et al 2002]. 
7.4 Mycophenolate mofetil 
Mycophenolate mofetil (MMF) is a reversible inhibitor of inosine monophosphate 
dehydrogenase (IMPDH) in purine biosynthesis. MMF is selective for the de novo pathway 
critical to lymphocytic proliferation and activation. Because of favorable results in other 
glomerular diseases, mycophenolate mofetil has also been evaluated in FSGS. Although the 
experience is limited, the suggested dose is 750-1000 mg twice daily in patients who are 
refractory to corticosteroids and in whom calcineurin inhibitors may not be appropriate. 
However, adequate randomized studies supporting this approach are lacking (Cattran DC et 
al. 2004). If mycophenolate is being considered, cyclosporine should not be used concurrently. 
Mycophenolate can be either used alone or in combination with corticosteroids.  
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7.5 Monoclonal antibody treatment 
Rituximab: Rituximab is an anti CD20 chimeric monoclonal antibody. Case reports have 
suggested rituximab may be effective in treating patients with minimal change nephropathy 
and FSGS. (Peters HP et al 2008). .Four patients with nephrotic syndrome due to minimal 
change nephropathy or FSGS were treated with rituximab because of failure of or 
intolerance to the standard immunosuppressive therapy. Other cases of FSGS reported in 
the literature (6 pediatric patients) that were successfully treated with rituximab were also 
included. Complete remission was reported within 1 month for a 7-year-old boy with FSGS 
during treatment with rituximab and concurrent treatment with mycophenolate, low-dose 
prednisolone (prednisone), and tacrolimus. Controlled trials are needed to further evaluate 
the efficacy of rituximab in FSGS.  
Fresolimumab: Recently a phase one trial (Trachtman H. et al 2011) has been completed 
which evaluated the safety and pharmacokinetics of single-dose infusions of fresolimumab, 
a human monoclonal antibody that inactivates all forms of transforming growth factor-beta 
(TGF-β), in a phase I open-label, dose-ranging study. Patients with biopsy-confirmed, 
treatment-resistant, primary FSGS with a minimum estimated glomerular filtration rate 
(eGFR) of 25 ml/min per 1.73m2, and a urine protein to creatinine ratio over 1.8mg/mg 
were enrolled. All 16 patients completed the study in which each received one of four 
single-dose levels of fresolimumab (up to 4mg/kg) and was followed for 112 days. 
Fresolimumab was well tolerated with pustular rash, the only adverse event, developing in 
two patients. Single-dose fresolimumab was well tolerated in patients with primary resistant 
FSGS. Additional evaluation in a larger dose-ranging study is necessary. 
7.6 Antifibrotic agents  
Pirfenidone has been shown to have therapeutic potential in fibrotic diseases, although the 
mechanism of action is not well understood. It has been shown to reduce transforming 
growth factor-β 1 production, antagonize TNF- signaling, and scavenge reactive oxygen 
species. It also reduces fibrosis and prevents loss of glomerular filtration in animal models 
of renal disease. An open-label trial evaluated the safety and efficacy of pirfenidone in 
patients with idiopathic and post adaptive FSGS. Pirfenidone had no effect on BP or 
proteinuria but it did preserve renal function. Controlled trials are needed to further 
evaluate the efficacy of pirfenidone in FSGS (Cho ME. et al 2007). 
Rosiglitazone: Renal mesangial cells express peroxisome proliferator-activated receptor 
(PPAR –gamma). PPAR-gamma activation, can exhibit anti-inflammatory effects. 
Weissgarten et al (2006) demonstrated that PPAR-gamma activation by rosiglitazone 
resulted in decreased manifestation of inflammatory hallmarks, including inhibition of 
mesangial cell proliferation, downregulation of apoptosis and blunted responsiveness to 
angiotensin II in animal models. FONT-I (a phase 1 clinical trial) showed that this agent was 
safe and well tolerated in 11 patients with biopsy-demonstrated FSGS. The results of further 
studies are awaited. 
Despite all attempts, some patients continue to deteriorate and progress to ESRD. Patients 
and their families should be counselled in detail regarding the treatment options for ESRD 
so that they can choose appropriate treatment tailored to their life style among maintenance 
hemodialysis, continuous ambulatory peritoneal dialysis, or renal transplantation. FSGS 
may recur in the transplanted kidney, but most centers do not consider this a 
contraindication for renal transplantation.  
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Secondary FSGS treatment management is directed toward the etiology or associated 
disorder. For example, discontinuing pamidronate in pamidronate induced FSGS, and in 
HIV-associated FSGS, HAART is associated with remission of proteinuria and preservation 
of renal function. In heroin-associated FSGS, discontinuation of the drug may result in 
remission of proteinuria and improvement in renal function.  
8. Prognosis 
Prognosis of idiopathic FSGS is variable. Important prognostic factors are, the amount of 
proteinuria, the level of plasma creatinine, the morphological subtype, and the response to 
therapy as listed in table 3. Korbet SM (1999) described that nephrotic patients with FSGS, 
particularly those with massive proteinuria, have a significantly poorer prognosis than non-
nephrotic patients, with 50% progressing to end-stage renal disease (ESRD) over 3-8 years as 
compared with a 10-year survival of >80%, respectively. In addition, the recurrence rate of 
this lesion is high in transplanted patients with primary FSGS. When clinical and 
histological features at presentation have been evaluated by multivariate analysis, the 
significant positive predictors of progression to ESRD have consistently been the serum 
creatinine (>1.3 mg/dl), amount of proteinuria and the presence of interstitial fibrosis (> or 
=20%). The one factor which is a significant negative predictor of progression to ESRD is the 
achievement of a remission in proteinuria. Unfortunately, spontaneous remissions are rare 




1. Clinical features at the time of biopsy 
a. Nephrotic range proteinuria or massive proteinuria 
b. Elevated serum creatinine 
c. Black race 
2. Histopathologic features at the time of biopsy 
a. Collapsing variant  
b. Tubulointerstitial fibrosis 
3. Clinical features during the course of the FSGS 
a. Failure to achieve partial or complete remission. 
_________________________________________________________________________________ 
Table 3. Risk factors for progressive loss of renal function in FSGS  
Thomas DB et al. (2006) described that the morphological subtype identified on renal biopsy 
also provided useful prognostic information. The collapsing variant, the main variant seen 
in HIV-induced FSGS, is associated with a worse prognosis than the other forms. The tip 
variant has a better prognosis than the other forms. 
9. Summary 
Focal segmental glomerulosclerosis is still largely an idiopathic disease but in the recent 
past, more genetic mutations and secondary causes have been described. As more and more 
pathogenetic mechanisms involved in idiopathic FSGS are coming into light and more 
secondary causes of FSGS are described, the occurrence of true idiopathic FSGS diagnosis is 
www.intechopen.com
 An Update on Glomerulopathies – Clinical and Treatment Aspects 
 
40
decreasing and thus the frequency of the latter is often overstated. Other than the genetic 
and secondary causes of FSGS, the treatment strategies are still not based upon multiple 
large randomized controlled trials, and in fact are based upon predominantly anecdotal 
experiences. Still there are more questions than the answers for the pathogenesis, 
classification, treatment and prognosis of this an almost a century old disease. This 
clincopathologic entity still remains a challenge for the nephrologists and transplant 
physicians. 
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